To address this issue, we analysed 12 cases with established EGFR mutation status for therapeutic purposes (each 6 cases with/without EGFR mutations) and evaluated the tumor specimens for hamartin, p-tuberin and p-mTOR expression. This evidence concerns the gene MTOR and neoplasm.